General Information of Drug (ID: DMG6ZU4)

Drug Name
Lanreotide acetate
Synonyms
Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel
Indication
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1096.3
Logarithm of the Partition Coefficient (xlogp) 2.5
Rotatable Bond Count (rotbonds) 17
Hydrogen Bond Donor Count (hbonddonor) 13
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
Clearance
The clearance of drug is 23.1 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 22 days [2]
Vd
The volume of distribution (Vd) of drug is 15.1 L []
Chemical Identifiers
Formula
C54H69N11O10S2
IUPAC Name
10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
Canonical SMILES
CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
InChI
InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
InChIKey
PUDHBTGHUJUUFI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
71349
CAS Number
108736-35-2
DrugBank ID
DB06791
TTD ID
D0M2YE
ACDINA ID
D01195
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acromegaly
ICD Disease Classification 5A60.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Somatostatin receptor type 2 (SSTR2) DTT SSTR2 9.79E-07 -0.38 -0.65
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lanreotide acetate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Lanreotide acetate caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [3]
Pexidartinib DMS2J0Z Major Decreased metabolism of Lanreotide acetate caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [4]
Palbociclib DMD7L94 Moderate Decreased metabolism of Lanreotide acetate caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [3]
Ripretinib DM958QB Moderate Decreased metabolism of Lanreotide acetate caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [5]
Avapritinib DMK2GZX Moderate Decreased metabolism of Lanreotide acetate caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [3]
177Lu-DOTATATE DMT8GVU Moderate Interference of cell/tissue uptake of Lanreotide acetate by 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [6]
MK-1439 DM215WE Minor Decreased metabolism of Lanreotide acetate caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [7]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Lanreotide acetate caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Lanreotide acetate caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [9]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Lanreotide acetate caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Selpercatinib DMZR15V Moderate Decreased metabolism of Lanreotide acetate caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [3]
IPI-145 DMWA24P Moderate Decreased metabolism of Lanreotide acetate caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Lanreotide acetate caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [12]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Lanreotide acetate caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [13]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Lanreotide acetate caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [3]
Entrectinib DMMPTLH Moderate Decreased metabolism of Lanreotide acetate caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [14]
Lefamulin DME6G97 Moderate Decreased metabolism of Lanreotide acetate caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [15]
Darolutamide DMV7YFT Minor Decreased metabolism of Lanreotide acetate caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [16]
Upadacitinib DM32B5U Moderate Decreased metabolism of Lanreotide acetate caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [17]
Larotrectinib DM26CQR Moderate Decreased metabolism of Lanreotide acetate caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [5]
LEE011 DMMX75K Moderate Decreased metabolism of Lanreotide acetate caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [5]
⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Water E00035 962 Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lanreotide Acetate eq 60mg base/0.2ml solution eq 60mg base/0.2ml Solution Subcutaneous
Lanreotide Acetate eq 90mg base/0.3ml solution eq 90mg base/0.3ml Solution Subcutaneous
Lanreotide Acetate eq 120mg base/0.5ml solution eq 120mg base/0.5ml Solution Subcutaneous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Product Information. Lutathera (lutetium Lu 177 dotatate). Advanced Accelerator Applications, New York, NY.
7 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
8 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
9 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
10 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
11 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
12 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
13 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
14 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
15 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
16 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
17 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.